Janet Ritchie
Oklahoma City, OKNPI 1437374592
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,651 of the $2,506 with a category attached, or 65.9%. 20 manufacturers reported payments, led by Axonics, Inc. at 45.8% of the total. Reporting peaked in 2023 at $1,556 and has fallen 87.9% since, to $189 in 2024.
Across 89 payments — averaging $28.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$1K
- AbbVie$442
- Astellas Pharma US Inc$304
- Organon$145
- Sumitomo Pharma America, Inc.$99
- Bayer$86
- plus $283 from 14 others
What the payments were for
- Travel & lodging$67027%
- Food & beverage$1,65166%
- Education$1857%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 13 | $1,148 |
| AbbVie | 27 | $442 |
| Astellas Pharma US Inc | 12 | $304 |
| Organon | 11 | $145 |
| Sumitomo Pharma America, Inc. | 5 | $99 |
| Bayer | 5 | $86 |
| Mylan Pharmaceuticals Inc. | 2 | $40 |
| Millicent US Inc | 2 | $36 |
| Kowa Pharmaceuticals America, Inc. | 1 | $24 |
| Johnson & Johnson | 1 | $23 |
| Agile Therapeutics, Inc. | 1 | $22 |
| Mayne Pharma Commercial LLC | 1 | $20 |
| Baudax Bio Inc. | 1 | $16 |
| Amgen | 1 | $16 |
| Sage Therapeutics, LLC | 1 | $16 |
| Medtronic | 1 | $14 |
| Pfizer | 1 | $14 |
| Antares Pharma, Inc. | 1 | $14 |
| Pacira Pharmaceuticals Incorporated | 1 | $14 |
| Avion Pharmaceuticals | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axonics$740
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 12 | $11,062 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 31 | $425 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $99 | $11,06212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Oklahomaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.